Correlation Between Apellis Pharmaceuticals and Day One

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Apellis Pharmaceuticals and Day One at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Apellis Pharmaceuticals and Day One into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Apellis Pharmaceuticals and Day One Biopharmaceuticals, you can compare the effects of market volatilities on Apellis Pharmaceuticals and Day One and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Apellis Pharmaceuticals with a short position of Day One. Check out your portfolio center. Please also check ongoing floating volatility patterns of Apellis Pharmaceuticals and Day One.

Diversification Opportunities for Apellis Pharmaceuticals and Day One

0.86
  Correlation Coefficient

Very poor diversification

The 3 months correlation between Apellis and Day is 0.86. Overlapping area represents the amount of risk that can be diversified away by holding Apellis Pharmaceuticals and Day One Biopharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Day One Biopharmaceu and Apellis Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Apellis Pharmaceuticals are associated (or correlated) with Day One. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Day One Biopharmaceu has no effect on the direction of Apellis Pharmaceuticals i.e., Apellis Pharmaceuticals and Day One go up and down completely randomly.

Pair Corralation between Apellis Pharmaceuticals and Day One

Given the investment horizon of 90 days Apellis Pharmaceuticals is expected to generate 0.76 times more return on investment than Day One. However, Apellis Pharmaceuticals is 1.32 times less risky than Day One. It trades about -0.12 of its potential returns per unit of risk. Day One Biopharmaceuticals is currently generating about -0.14 per unit of risk. If you would invest  3,190  in Apellis Pharmaceuticals on December 28, 2024 and sell it today you would lose (762.00) from holding Apellis Pharmaceuticals or give up 23.89% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy100.0%
ValuesDaily Returns

Apellis Pharmaceuticals  vs.  Day One Biopharmaceuticals

 Performance 
       Timeline  
Apellis Pharmaceuticals 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Apellis Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
Day One Biopharmaceu 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Day One Biopharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Apellis Pharmaceuticals and Day One Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Apellis Pharmaceuticals and Day One

The main advantage of trading using opposite Apellis Pharmaceuticals and Day One positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Apellis Pharmaceuticals position performs unexpectedly, Day One can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Day One will offset losses from the drop in Day One's long position.
The idea behind Apellis Pharmaceuticals and Day One Biopharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Other Complementary Tools

Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Global Correlations
Find global opportunities by holding instruments from different markets
Money Managers
Screen money managers from public funds and ETFs managed around the world